ARTICLE | Clinical News

Soluble Ferric Pyrophosphate: Additional Phase IIb data

December 13, 2010 8:00 AM UTC

Additional data from a double-blind, dose-ranging, North American Phase IIb trial in 131 dialysis patients showed that 10 µg/dL SFP met the secondary endpoint of significantly increasing hemoglobin from baseline vs. placebo after a mean treatment duration of 13.4 weeks (p=0.049). The 5, 12 and 15 µg/dL doses of SFP missed the endpoint (p=0.234, 0.375 and 0.625, respectively). Additionally, the 12 µg/dL dose of SFP led to a significant 13% reduction from baseline in erythropoiesis stimulating agent (ESA) dose vs. placebo (p=0.044), while the 5, 10 and 15 µg/dL doses led to non-significant reductions on the endpoint (p=0.713, 0.695 and 0.882, respectively). Data were presented at the American Society of Nephrology meeting in Denver. ...